Risk-Based Ultrasound Screening for Thyroid Cancer in Obese Patients is Cost-Effective

Stephanie Cham,¹ Kyle Zanicco,² Cord Sturgeon,² Michael W. Yeh,¹ and Avital Harari¹

Background: A higher body mass index (BMI) is associated with more advanced stages of thyroid cancer. Screening obese patients for thyroid cancer has been proposed but has yet to be examined for cost-effectiveness. The objective of this study was to assess the cost-effectiveness of ultrasound (US) screening of obese patients for thyroid cancer.

Methods: A decision-tree model compared cost savings for the following: (i) base case scenario of an obese patient with thyroid nodule found by palpation, (ii) universal US screening of all obese patients, and (iii) risk-based US screening in obese patients. Risk-based screening consisted of patients who had at least one of four major identified risk factors for thyroid cancer (family history of thyroid cancer, radiation exposure, Hashimoto's thyroiditis, and/or elevated thyrotropin). Patients with nodules underwent established treatment and management guidelines. The model accounted for recurrence, complications, and long-term treatment/follow-up for five years. Outcome probabilities were identified from a literature review. Costs were estimated using a third-party payer perspective. Sensitivity analyses were performed to examine the impact of risk factor prevalence and US cost on the model.

Results: The resulted costs per patient were \$210.73 in the base case scenario, \$434.10 in the universal US screening arm, and \$166.72 in the risk-based screening arm. Risk-based screening remained cost-effective until more than 14% of obese patients had risk factors and with a wide variation of US costs (\$0–\$1113).

Conclusion: Risk-based US screening in selected obese patients with risk factors for thyroid cancer is cost-effective. Recommendations for screening this subgroup will result in cost savings and a likely decreased morbidity and mortality in this subpopulation with more aggressive disease.

Introduction

THYROID CANCER IS THE MOST COMMON endocrine cancer, with a U.S. prevalence of approximately 500,000 in 2009 (1). In the past few decades, the incidence and prevalence of thyroid cancer has shown an increasing trend in the United States (2). There has also been a concurrent rising prevalence of obesity within the population (3). Obesity has been linked as a risk factor for a number of diseases, including cardiovascular disease, diabetes mellitus, and various forms of cancer. Thyroid cancer has also been shown to have an increased incidence in the obese population (4–7).

Our group has recently shown that a higher body mass index (BMI) is also associated with a more advanced stage and more aggressive forms of papillary thyroid cancer (8). Importantly, advanced stage and aggressive forms of thyroid cancer are strongly correlated with higher morbidity (recurrence, surgical complications, etc.) and mortality. Evidence

has also indicated that if thyroid cancer is detected at an early stage and given appropriate initial treatment, its long-term impact includes lower recurrence and mortality rates (9–11).

Rising healthcare costs have resulted in an increasing interest in cost-effective methods to prevent and manage surgical and nonsurgical disease. Studies on the cost and health benefits of screening have primarily focused on commonly screened cancers, such as mammography for breast cancer (12,13). However, thyroid cancer is also a cancer recommended for early detection by the American Cancer Society (12). Screening, treatment, and long-term follow-up of thyroid cancer extends for many years and can impact quality of life, particularly in those with more aggressive and advanced disease (14,15).

One possible explanation for advanced thyroid cancers in patients with a higher BMI is delayed diagnosis due to difficulty palpating an obese neck. Thus, we speculate that obese patients may benefit from screening for early detection of

¹Department of Surgery, Section of Endocrine Surgery, University of California, Los Angeles, Los Angeles, California.

²Department of Surgery, Feinberg School of Medicine, Northwestern University, Evanston, Illinois.

thyroid nodules. Ultrasound (US) is the initial diagnostic imaging modality for thyroid nodules and has a relatively high sensitivity (84–89%) and specificity (83–96%) (16–18). US has been used recently with good success to screen obese patients for thyroid cancer (7). Here, we examine the cost-effectiveness of US screening for thyroid cancer in obese patients, a particularly challenging population.

Materials and Methods

Reference case definition

The reference case is a 46-year-old obese patient with unknown thyroid pathology whose thyroid nodule would be detected by palpation. The age of 46 was chosen so that the American Joint Committee on Cancer Staging (AJCC) criteria on staging would be applicable and that all four stages would be relevant (19). The patient is otherwise healthy with no previous history of neck operations. Obesity in this study is defined as a BMI $>30 \text{ kg/m}^2$, which is the definition of obesity by the National Heart, Lung, and Blood Institute (20). It is a conservative definition, as there have been studies that have shown an increased risk of thyroid cancer in BMIs as low as 25 kg/m^2 (21).

Decision model

A cost–utility analysis was conducted using a decision-tree model with TreeAge statistical software (22). The first pathway follows the reference case obese patient who is sent for US if a nodule is palpated in the neck. This situation is the current method of evaluation of most obese patients. Two additional alternative management pathways were created: (i) any obese patient screened with US; and (ii) an obese patient screened with US who also had at least one known risk factor for thyroid cancer (including family history of thyroid cancer, history of significant radiation exposure, Hashimoto's thyroiditis, and/or elevated thyrotropin (TSH); Fig. 1) (23–30). The model had a cycle length of five years (enough time for follow-up and/or recurrence of thyroid cancer) and included postoperative surveillance, treatment, and mortality.

Basic structure. The model's event pathways followed current practice opinions of the American Thyroid Association and that of expert clinical judgment on the management of thyroid cancer. Pathway and outcome probabilities were based on an extensive literature review (Table 1). When no literature existed for a specific probability in the decision model, expert opinion was used.

Risk factors. Four major risk factors for thyroid cancer were identified, and a literature search was conducted to examine their relative risk of malignancy. An average relative risk (RR) for each risk factor was calculated from a range seen in the literature: family history of thyroid cancer (RR 5.0; range 4.1–10), radiation exposure (RR 6.5; range 1.69–11.), Hashimoto's thyroiditis (RR 2.5, range 1.6–2.96), and elevated TSH (RR 5.7, range 1–11.2) (20–27). This resulted in an average RR of 5.0 for all four risk factors, which was used in determining subsequent pathway probabilities, affecting the outcome probabilities within the third arm (Table 2). Based on a literature search, we used a value of 9.5% for the probability

of an obese patient to present with risk factors, which was the value for the most common risk factor seen in the population (Table 2) (31–33).

Probabilities. Importantly, base case probabilities (top arm, Fig. 1) for stage I/II, III, and IV distribution were calculated using the odds ratio of 2.57 for the increased odds of an obese patient presenting with stage III or IV disease, based on a previous study performed by our group (8). Probabilities of more aggressive and advanced disease were thus presumed for the base case based on a previous literature review of the increased risk of thyroid cancer aggressivity within obese patients. This is why these percentages look skewed and much higher than what is normally expected. The all-US screening and risk-based US screening branches assumed distribution of disease stage of the general population using the National Cancer Institute's Surveillance, Epidemiology and End Results database (1).

The probability of receiving an US in the base case was 5%, based on the relative rate of palpable thyroid nodules in our base case population. We estimated that 80% would then progress to fine needle aspiration biopsy (FNAB) (34,35). In the US screening group, 100% received US screening, and a conservative estimate of 10% were assumed to progress to FNAB. Expert opinion was used to calculate this probability based on the relative prevalence of thyroid nodules in a 46-year-old female (30%) (34) combined with the high sensitivity of US for microcarcinomas and incidentalomas. In the risk-based screening group (third arm), based on prevalence data, as noted above, 9.5% of obese patients were estimated to have at least one risk factor for thyroid cancer and would progress to US screening. Based on the relative risk of 5.0 for having a malignant thyroid nodule, a calculated 20% were assumed to progress to FNAB (Table 1).

The probabilities of FNAB and lobectomy results were determined from Reports from the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference and the American Thyroid Association (Table 1). The base case probability of FNAB results were 10% malignant, 20% indeterminate, and 70% benign (36,37). Overdetection of thyroid nodules with US screening was anticipated, and an adjusted decreased malignancy rate was used for the US screening group to 5% malignant, 20% indeterminate, and 75% benign. The relative risk of 5.0 for any one of the risk factors was used to determine the probability of FNAB results in the risk-based screening group, resulting in 20% malignant, 20% indeterminate, and 60% benign.

In our model, all indeterminate FNAB results include follicular neoplasm of undetermined significance, atypia of undetermined significance, follicular neoplasm, and suspicious for papillary thyroid cancer. These indeterminate FNAB results underwent lobectomy for definitive diagnosis. We did not choose total thyroidectomy for "suspicious for malignancy" FNAB results or for indeterminate thyroid nodules that have a history of radiotherapy or a family history of thyroid cancer, although we recognize that many patients are offered this as treatment for various individualized reasons. Since it is not standardized, we chose to use lobectomy as a formal, more conservative diagnostic surgical option followed by completion thyroidectomy if the nodule was determined malignant.

FIG. 1. Decision-tree model for thyroid cancer management of obese patients.

TABLE 1. SUMMARY OF MODEL VARIABLE PROBABILITIES

<i>Model variables</i>	<i>Probabilities</i>	<i>Citation</i>
Base case probabilities:		
US following palpation	0.05	(34,35)
No further testing	0.95	(34,35)
FNAB following palpation and US	0.8	(35)
No FNAB following palpation and US	0.2	(35)
FNAB result malignant	0.1	(37)
FNAB result indeterminate	0.2	(37)
FNAB result benign	0.7	(37)
Indeterminate FNAB result—malignant	0.625	(36), AVG
Indeterminate FNAB result—benign	0.375	(36), AVG
Malignant—stage I/II	0.43	(1,8)
Malignant—stage III	0.46	(1,8)
Malignant—stage IV	0.11	(1,8)
US screening probabilities:		
US	1	
No further testing	0	
FNAB following US screening	0.1	(34,57)
No FNAB following US screening	0.9	(34,57)
FNAB result malignant	0.05	(37), EO
FNAB result indeterminate	0.2	(37), EO
FNAB result benign	0.75	(37), EO
Indeterminate FNAB result—malignant	0.625	(36), AVG
Indeterminate FNAB result—benign	0.375	(36), AVG
Malignant—stage I/II	0.7	(1,8)
Malignant—stage III	0.25	(1,8)
Malignant—stage IV	0.05	(1,8)
Risk-based US screening probabilities:		
US following identification of risk factor	0.095	(23,31–33)
No further testing	0.905	(23,31–33)
FNAB following US screening	0.2	(34,57), EO
No FNAB following US screening	0.8	(34,57), EO
FNAB result malignant	0.2	(37), EO
FNAB result indeterminate	0.2	(37), EO
FNAB result benign	0.6	(37), EO
Indeterminate FNAB result—malignant	0.89	(33), AVG, EO
Indeterminate FNAB result—benign	0.11	(33), AVG, EO
Malignant—stage I/II	0.7	(1,8)
Malignant—stage III	0.25	(1,8)
Malignant—stage IV	0.05	(1,8)
Follow-up/complications		
RAI for stage I/II	0.38	(41)
RAI for stage III/IV	1	(37)
RLN injury for base case	0.17	(8,14,54)

(continued)

TABLE 1. (CONTINUED)

<i>Model variables</i>	<i>Probabilities</i>	<i>Citation</i>
RLN injury for US screening	0.019	(8,14,54)
RLN injury for reoperation	0.06	(42), EO
Permanent hypoparathyroidism for initial surgery	0.019	(14)
Permanent hypoparathyroidism for reoperation	0.05	(14), Text, EO
Recurrence—stage I/II	0.06	(43,44)
Recurrence—stage III	0.27	(43,44)
Recurrence—stage IV	0.609	(43,44,58)
Chemotherapy—stage IV only	0.06	(58)

US, ultrasound; FNAB, fine-needle aspiration biopsy; EO, expert opinion used; AVG, average of range of values used; RAI, radioiodine; RLN, recurrent laryngeal nerve.

We did not include any molecular testing in this model. All patients with malignant FNAB results underwent definitive surgery (total thyroidectomy with or without lymph node removal depending on stage). The probability of a malignant nodule found on lobectomy (62.5%) was assumed to be the same across all groups. We recognize that some FNABs will be determined “insufficient” or “nondiagnostic.” In this model, we assumed that those people re-entered the model and had subsequent FNAB diagnoses. To account for this cost, the FNAB cost was increased by 10% (38).

The AJCC system was used to stratify those diagnosed with thyroid cancer into three different groups: local (stage I/II), regional (stage III), and remote (stage IV) disease on presentation. The stratification was chosen because clinical outcomes (recurrence, mortality, complications) and cost-effectiveness (costs, extent of long-term follow-up, and quality of life) can be clearly distinguished between these groups. This final endpoint was chosen due to significant differences in the relative risk of thyroid cancer seen in obese patients.

Follow-up. Five-year follow-up of thyroid cancer management followed general management guidelines. The length of five years was chosen given the increased aggressiveness in obese patients of this disease. Most patients who recur with this type of aggressive disease or who have morbidity from this disease do so within five years (39). Additionally, a considerable difference in five-year mortality has been shown in those presenting with later stages (40).

The probability of receiving radioactive iodine (RAI) was estimated to follow current trends. Approximately 38% of the population receives RAI in localized disease, and approximately 100% receive RAI in regional and remote disease (37,41). We determined a 6% rate of chemotherapy only for those with stage IV disease. Recurrence rates for each stage of illness were determined based on a literature review (Table 1).

Complications. The risk of recurrent laryngeal nerve (RLN) injury for those with US screening was that of the general population (1.9%). Risk of RLN injury in the base

TABLE 2. RISK FACTORS

<i>Risk factor</i>	<i>Relative risk</i>	<i>Citation</i>
Relative risk of malignancy for those with risk factors (value averaged from four risk factors below):	5.0	
Family history of thyroid cancer	5.0	(23–25), AVG
Radiation exposure	6.5	(26)
Hashimoto's thyroiditis	2.5	(27,28), AVG
Elevated TSH	5.7	(29,30), AVG
	<i>Probability</i>	
Probability of at least one risk factor (highest value from risk factors below):	0.095	
Family history of thyroid cancer	0.06	(23,31), AVG
Radiation exposure	Unavailable	—
Hashimoto's thyroiditis	0.046	(32)
Elevated TSH	0.095	(33)

TSH, thyrotropin.

case nonscreening was set higher (17%). This was based on previous studies performed by our group, which showed a significantly higher rate of preoperative vocal cord paralysis due to local invasion (odds ratio 9.2) (8). Risk of permanent hypoparathyroidism was similar across all groups for an initial operation (1.9%) and reoperation (5%) (14,42). The recurrence rate was assumed to be similar across all groups and depended on the stage (43,44) (Table 1).

Costs

Costs for management, surgery, and follow-up are summarized in Table 3. The costs for laboratory tests were obtained from the 2012 Medicare Clinical Laboratory Fee Schedule (45). Direct medical costs were estimated using reported Medicare charge and reimbursement data. The inpatient costs were estimated by calculating the Medicare cost-to-charge ratio of 0.145 for Diagnosis-Related Groups (DRGs) 627 from the Medicare Provider Analysis Review database. Anesthesia costs were calculated using the following formula: (base units + time units + modifying units) × conversion factor, where base unit = 6, time units = # min procedure/15, and conversion factor national average = 21.10. The outpatient costs were estimated on the basis of national facility rates from the Medicare Hospital Outpatient Prospective Payment system for their corresponding outpatient Current Procedural Terminology (CPT) codes. Costs of complications and chemotherapy were obtained from previous studies (46,47).

Total costs for each branch of the decision-tree analysis can be seen in Table 3. In the decision analysis tree, “no further testing” resulted in a cost of \$0. “Follow-up” of benign FNAB consisted of an US, laboratory testing (free thyroxine and TSH), and a clinician/endocrinology visit. “Follow-up” of benign lobectomy consisted of an US, laboratory testing (free thyroxine and TSH), a clinician/endocrinology visit, and levothyroxine costs (assuming a 35% patient need for

levothyroxine replacement) (48). Treatment costs of each stage incorporated preoperative US, surgical consult, inpatient costs, surgical costs (surgery, anesthesia, cytopathology), levothyroxine costs, and five-year follow-up. Five-year follow-up for each stage consisted of labs (free thyroxine and TSH), routine neck US at each visit, and the cost of clinician/endocrinology visits. Stage I/II patients were followed at six months, and one, three, and five years. Stage III and stage IV patients were followed at six months and every year for five years, and received a single diagnostic whole body scan. For those receiving RAI, lab values of stimulated TSH and thyroglobulin antibodies were drawn every one, three, and five years.

Costs of recurrence and/or chemotherapy were built into each stage based on probability. Complication costs (surgical morbidities, RLN injury, and hypoparathyroidism) and chemotherapy treatment were estimated from costs gathered from previous studies (45–47). The cost of recurrence was based on the use of a modified radical neck dissection for surgery, but otherwise assumes the patient re-enters the decision model and incurs costs of treatment and probability of complications. Calculations of costs and probabilities of recurrence were similar to estimates of other studies (14,37,49).

Sensitivity analysis

Sensitivity analysis was used to test the level of uncertainty of reference case assumptions. Clinically relevant variables that affect the analysis the most were tested independently across a range of possible values to determine the impact on cost savings and effectiveness. US costs varied between \$0 and \$1200. The impact of the prevalence of various risk factors for thyroid cancer was examined and varied between 0% and 20%. A total model sensitivity analysis of all variables could not be done, since the sum of the probabilities of each arm (e.g., FNAB result malignant) are nonindependent due to clinical variability (e.g., risk factors, prevalence).

Results

Cost analysis

A summary of outcomes from the decision-tree analysis is given in Table 4. The average cost per person for evaluation of a thyroid nodule in our base case scenario without screening was \$210.73. The average cost of US screening for all obese patients for thyroid cancer was calculated to be \$434.10 per person and was not cost-effective in relation to the base case scenario. However, risk-based screening was more cost-effective than the base case, resulting in a total per person cost of \$166.72, a cost savings of 21% in comparison to the base case.

Sensitivity analysis

As the cost of US was between \$0 and \$1200, the risk-based screening strategy remained more cost-effective relative to the base case (up to an US cost of \$1113) per obese patient screened (Fig. 2). When the prevalence of risk factors was varied between 0% and 20%, the risk-based arm continued to be cost-effective until more than 14% of obese

TABLE 3. SUMMARY OF COSTS

<i>Type of cost</i>	<i>Cost (\$)</i>	<i>Citation</i>	<i>DRG, ICD-9, CPT, or LFSC</i>
Initial management—palpation, screening, risk-based screening (30 min office consult—history, physical)	74.88	(49)	CPT Code: 99203
Ultrasound (initial)	123.56	(49)	CPT Code: 76536
No further testing (after initial management)	0		
FNAB (total)	260.01 (with 10% increase to account for insufficient diagnoses)	(38)	
TSH assay	23.80	(45)	LFSC: 84443
Free thyroxine	12.77	(45)	LFSC: 84439
FNAB with US guidance	64.67	(49)	CPT Code: 10022
Cytopathology FNAB (evaluation and interpretation/report)	135.13	(49)	CPT Code: 88172, 88173
FNAB malignant arm—stage I/II management (total), all arms	7244.69		
Preop US	123.56	(49)	CPT Code: 76536
Surgical consult	67.73	(49)	CPT Code: 99242
Inpatient TTX cost 45–64-year-old for stage I/II (1 day)	2934.27	(59)	DRG 627, ICD-9 06.4
Total thyroidectomy for > 1 cm	925.14	(49)	CPT Code: 60240
Anesthesia (2 h)	295.4	(49)	CPT Code: 00320
Cytopathology	101.43	(49)	CPT Code: 88172, 88173
Average 5-year follow-up—stage I/II	1318.92	(37,45,49)	35% of patients received low-dose RAI
Recurrence (6%) plus Complications (RLN 1.9%, hypoparathyroidism 1.9%)	720.69		
Cost of levothyroxine	757.55	(48)	
FNAB malignant arm—stage III management (total)	13,252.18 (base), 11,626.23 (screening)		
Preop US	123.56	(49)	CPT Code: 76536
Surgical consult	67.73	(49)	CPT Code: 99242
Total thyroidectomy for malignancy with limited neck dissection	1323.04	(49)	CPT Code: 60252
Inpatient TTX cost 45–64-year-old for stage III (1.4 days)	4107.98	(59)	DRG 627, ICD-9 06.4
Anesthesia (3 h)	379.80	(49)	CPT Code: 00320
Cytopathology	101.43	(49)	CPT Code: 88172, 88173
5-year follow-up—stage III with low-dose RAI	2297.69	(49)	
Recurrence (27%) plus complications (RLN 1.9–17%, hypoparathyroidism 1.9%)	2467.23–4093.40		
Cost of levothyroxine	757.55	(48)	
FNAB malignant arm—stage IV management (total)	18,891.22 (base); 17,264.82 (screening)		
Preop US	123.56	(49)	CPT Code: 76536
Surgical consult	67.73	(49)	CPT Code: 99242
Total thyroidectomy with radical neck dissection	1682.48	(49)	CPT Code: 60254
Inpatient TTX cost 45–64-year-old for stage IV (2 days)	5868.54	(59)	DRG 627, ICD-9 06.4
Anesthesia (4 h)	464.20	(49)	CPT Code: 00320
Cytopathology	101.43	(49)	CPT Code: 88172, 88173
5-year follow-up—stage IV with high-dose RAI	2703.67	(49)	
Recurrence (61%), chemotherapy (6%), plus Complications (RLN 1.9–17%, hypoparathyroidism 1.9%) cost	5495.66–7122.06		
Cost of levothyroxine	757.55	(48)	

(continued)

TABLE 3. (CONTINUED)

<i>Type of cost</i>	<i>Cost (\$)</i>	<i>Citation</i>	<i>DRG, ICD-9, CPT, or LFSC</i>
FNAB indeterminate—lobectomy (total)			
Preop US	123.56	(42)	CPT Code: 76536
Surgical consult	67.73	(42)	CPT Code: 99242
Thyroid lobectomy, unilateral; with or without isthmusectomy	781.65	(42)	CPT Code: 60220
Inpatient lobectomy cost 45–64-year-old	2573.65	(59)	ICD 9 06.2
Anesthesia (1.5 h)	253.20	(42)	CPT Code: 00320
Cytopathology	101.43	(42)	CPT Code: 88172, 88173
Cost of levothyroxine	265.14	(48)	
Benign—follow-up (total)	210.62		
Initial US	123.56	(42)	CPT Code: 76536
TSH assay	23.80	(45)	LFSC: 84443
Free thyroxine	12.77	(45)	LFSC: 84439
Clinician/endocrinology visit	49.69	(45)	CPT Code: 99213
Lobectomy—malignant—stage I/II (total), all arms	6726.47		
Completion thyroidectomy	1102.48	(42)	CPT Code: 60260
Inpatient lobectomy cost 45–64-year-old for stage I/II (1 day)	1838.32	(51)	DRG 627, ICD-9 06.2
Anesthesia (1.5 h)	253.20	(42)	CPT Code: 00320
Cytopathology	101.43	(42)	CPT Code: 88172, 88173
Average 5-year follow-up—stage I/II	1318.92		
Recurrence (6%), plus complications (RLN 1.9%, hypoparathyroidism 1.9%) costs	720.68		
Cost of levothyroxine	757.55	(48)	
Lobectomy—malignant—stage III (total)	11,179.63 (base), 9553.23 (screening)		
Completion thyroidectomy	1102.48	(42)	CPT Code: 60260
Inpatient lobectomy cost 45–64-year-old for stage III (1.4 days)	2573.6		DRG 627, ICD-9 06.2
Anesthesia (1.5 h)	253.20	(42)	CPT Code: 00320
Cytopathology	101.43	(42)	CPT Code: 88172, 88173
5-year follow-up—stage III with low dose RAI	2297.69	(42)	
Recurrence (6%), plus complications (RLN 1.9–17%, hypoparathyroidism 1.9%) costs	2467.23–7093.63		
Cost of levothyroxine	757.55	(48)	
Lobectomy—malignant—stage IV (total)	15,716.43 (base), 14,090.63 (screening)		
Completion thyroidectomy	1102.48	(42)	CPT Code: 60260
Inpatient lobectomy cost 45–64-year-old for stage IV (2 days)	3676.64		DRG 627, ICD-9 06.2
Anesthesia (1.5 h)	253.20	(42)	CPT Code: 00320
Cytopathology	101.43	(42)	CPT Code: 88172, 88173
5-year follow-up—stage IV with high-dose RAI	2703.67	(42)	
Recurrence (61%), chemotherapy (6%), plus complications (RLN 1.9–17%, hypoparathyroidism 1.9%) costs	5495.66–7121.46		
Cost of levothyroxine	757.55	(48)	
FNAB—benign—follow-up (total)	210.62		
Initial US	123.56	(42)	CPT Code: 76536
TSH assay	23.80	(45)	LFSC: 84443
Free thyroxine	12.77	(45)	LFSC: 84439
Clinician/endocrinology visit	49.69	(45)	CPT Code: 99213

(continued)

TABLE 3. (CONTINUED)

Type of cost	Cost (\$)	Citation	DRG, ICD-9, CPT, or LFSC
Additional costs			
Reoperation	7625.77	(37,45,49)	DRG 627, ICD-9 193 40.4 (radical neck dissection, NOS)
RLN damage	10,770.84	(46)	
Calcitriol annually for hypoparathyroidism	896.68	(46)	
Chemotherapy (Sunitinib)	3345	(47)	
Recurrence costs (reoperation plus recurrence complication costs)	8316.85		
5-year follow-up costs (incorporated above)			
Serum TSH for RAI	23.80	(45)	LFSC: 84443
DxWBS (whole body scintigraphy)	320.63	(42)	CPT Code: 78018
TgAb	22.76	(45)	LFSC: 84432
TSH stimulated Tg	22.53	(45)	LFSC: 86800
TSH assay	23.80	(45)	LFSC: 84443
Follow-up clinical/endocrinology visit	49.69	(45)	CPT Code: 99213
Low-dose RAI ablation therapy	653.67	(14,49)	CPT Code: 79005
High-dose RAI ablation therapy	1059.65	(14,49)	CPT Code: 79005

LFSC, lab fee schedule codes.

patients were screened (Fig. 2). This indicated cost-efficiency had relatively low sensitivity to US cost variability and a limited sensitivity to a percent range of patients with risk factors.

Discussion

This study demonstrates that US screening is a cost-effective strategy for a subset of obese patients who have additional well-established risk factors for thyroid cancer, including: family history, radiation exposure, Hashimoto's thyroiditis, and/or elevated TSH. This suggests that obese patients over the age of 46 years who have known risk factors should undergo thyroid cancer US screening.

Other studies on the cost-effectiveness of initial diagnostic strategies and the management of thyroid carcinoma have been examined in the past (14,50–52). For example, FNAB was shown to be the most cost-saving diagnostic tool for distinguishing between benign and malignant nodules (50). Molecular testing for indeterminate FNABs has also been shown to be cost-effective (52). The use of calcitonin in routine screening of thyroid nodules has been implicated to be cost-effective with respect to life years saved (51). In the treatment of low-risk papillary thyroid cancer, total thyroidectomy was shown to be more cost-effective than hemithyroidectomy (14). However, to our knowledge, this is

the first study to evaluate the cost-effectiveness of screening in the long-term management of thyroid cancer in obese patients.

The utility of US screening in thyroid nodules has been studied. US in one study was shown to be the most effective initial diagnostic strategy to classify palpable nodules correctly as benign or malignant (but more costly relative to FNAB in short-term diagnostic costs) (50). The prevalence of both palpable and nonpalpable thyroid nodules in the general population of the United States is approximately 30% (with a slight increasing trend with age). Five percent of these are usually malignant (34). Because of this high prevalence of thyroid nodules in the general population with low malignancy potential, US screening has not been thought of as cost-effective for all patients.

The sensitivity of US in detecting nodules and their malignant potential is quite high. In one study, using a combination of sonographic features (e.g., irregular nodular margins, intranodular vascular pattern), 87% of cancers could be accurately detected with US alone (53). Thus, the use of initial US screening followed by FNAB would be an effective strategy for the management of nonpalpable nodules in the obese population, a subpopulation with known risk factors of aggressive disease.

Even though “no cancer screening” for the general population would be less costly, we as a society have accepted the cost of general screening for several types of cancers (colon, breast, cervical, etc.) in order to improve outcomes, reduce morbidity, and reduce mortality, all of which benefit society as a whole. Current recommendations made by the American Cancer Society indicate all individuals should be screened for thyroid cancer (12). However, thyroid cancer treatment and follow-up is long and extensive (14,15). Thus, screening for this cancer must take into account the perioperative costs and benefits. This is one of only a few studies to quantify the cost-effectiveness of screening, inclusive of the cost of long-term cancer surveillance. In those with higher

TABLE 4. HYPOTHETICAL OUTCOMES OF THYROID CANCER EVALUATION IN MODEL OF OBESE PATIENTS

Strategy	Average cost per patient	Incremental cost (% incremental cost)
No screening	\$210.73	—
Universal US screening	\$434.10	+ \$223.37 (106%)
Risk-based screening	\$166.72	– \$44.01 (– 21%)

FIG. 2. One-way sensitivity analysis of variable cost of ultrasound and risk-factor prevalence.

stage or more aggressive cancers, it is clear that the cost increases drastically and quality of life decreases. Obese patients are not only at a higher risk for thyroid cancer (4–7) but also have been shown to present with more aggressive thyroid cancers (8). They are also a much more vulnerable group due to the difficulty of physically palpating nodules in the obese neck.

Despite the increased risk of aggressive thyroid cancers in the obese, we have shown that in an obese patient, nonselective US screening was not cost-effective, despite the fact that they present in a later stage at baseline. This could be due to overdiagnosis of thyroid cancers and the requirement of further treatment and surveillance. Based on previous studies (23,31–33), however, we estimated that selected risk factors (family history of thyroid cancer, significant history of radiation exposure, Hashimoto's thyroiditis, and/or elevated TSH) were present in an average of 9.5% of obese patients with an average relative risk of malignancy of 5.0 (23–30). These values substantially decrease the number of patients receiving US screening and increase the probability of finding malignancy. By limiting the screening to those at high risk, this resulted in cost savings and afforded patients a higher quality of life relative to the base case scenario. This would suggest that one could prevent severe local and systemic complications in this subpopulation by using US screening.

Of note, Hashimoto's thyroiditis was included in the risk factors for thyroid cancer. We acknowledge that there has been controversy and conflicting data about the true effect of this risk factor on the occurrence of thyroid cancer. In our model, the effect is minimal. If this risk factor were eliminated, the analysis would use the same percentage of risk factors (9.5%), and the relative risk of more aggressive disease would be even higher in obese patients (increasing to 5.7 instead of 5.0). Thus, if anything, the effect we have shown by including Hashimoto's as a risk factor is more conservative. Our conclusions would more strongly support US screening if we eliminated this risk factor.

Studies have also shown that thyroid cancer disease-specific mortality rates increase in populations with delayed thyroid cancer treatment (9,10). Recurrence and metastatic

disease is highly dependent on the size and aggressiveness of the neoplasm when discovered (11). Surgical complications, disease management, and long-term follow-up are also dependent on the aggressiveness of the cancer (1,8,14,37,42–44,54). In our study, we found that if a nodule was malignant, a higher stage resulted in an overwhelming increase in the costs and quality-of-life changes in patients with thyroid cancer. Our analysis may have actually underestimated the benefit-to-cost ratio. The relatively high sensitivity and specificity of US, as compared to palpation, may even skew the proportion of screened patients toward lower stage cancers (I/II) due to earlier detection. Furthermore, our follow-up time period was only five years. The base case reference's potential remaining life expectancy is another 35 years, and an even more long-term analysis may have shown a greater benefit-to-cost ratio.

A potential limitation of the model is the assumption that obese patients will have the same cancer stage distribution as the normal population if screened with US. This would assume that obese patients and nonobese patients have the same pathophysiology of disease. It has been suggested, however, that another potential cause of more aggressive tumor types within the obese population is due to a difference in biology (55). Another limitation to our study is that certain variables required extrapolation or expert opinion when data were not available. The risk factors and certain probabilities were estimated from the nonobese population. However, these estimated values are unlikely to change the cost-effectiveness calculated, since they were used similarly across all groups compared.

An additional issue with the model is that we chose to do a thyroid lobectomy for those patients with indeterminate thyroid nodules even if they had a history of radiotherapy, a family history of thyroid cancer, or their diagnosis on FNAB was suspicious for malignancy. These patients are sometimes offered total thyroidectomies as an initial option given the high risk of malignancy in an indeterminate nodule in patients with those risk factors (50–70%) (56). However, this is not a standardized treatment protocol. Thus, we chose to use the more conservative and more costly surgical approach, which is to perform a lobectomy for diagnosis and a completion

thyroidectomy if the lesion was found to be malignant. Thus, it is not surprising that when we did rerun the model as though all patients with these risk factors got total thyroidectomies, it did not change the conclusion. In fact, it showed a greater cost-effectiveness to screening obese patients.

The risk factors chosen for this analysis were based on extensive literature review and expert opinion of the most well-known associations of the development of differentiated thyroid cancer (23–30). We chose to focus on the obese population due to the difficulties in screening, thus altering their initial presentation and the complications associated with their diagnosis. Future work of interest includes examining whether US screening retains its cost-effectiveness in the general population with these risk factors as well.

Conclusion

While we recognize that US screening of the general obese population may be unfeasible, we have found that in obese patients with established risk factors (family history, radiation exposure, Hashimoto's, elevated TSH), US screening for thyroid cancer is cost-effective. Thus, consideration for using US for thyroid cancer screening among targeted subgroups of obese patients is warranted and will likely decrease morbidity and mortality in this subpopulation with aggressive disease.

Acknowledgments

There are no outside sources of funding/support.

Author Disclosure Statement

The authors have nothing to disclose.

References

1. National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) Program About SEER. Available at: www.seer.cancer.gov/about/ (accessed January 2013).
2. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973–2002. *JAMA* **295**:2164–2167.
3. Flegal KM, Carroll MD, Kit BK, Ogden CL 2012 Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. *JAMA* **307**:491–497.
4. Kitahara CM, Platz EA, Freeman LE, Hsing AW, Linet MS, Park Y, Schairer C, Schatzkin A, Shikany JM, Berrington de Gonzalez A 2011 Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. *Cancer Epidemiol Biomarkers Prev* **20**:464–472.
5. Meinhold CL, Ron E, Schonfeld SJ, Alexander BH, Freedman DM, Linet MS, Berrington de Gonzalez A 2010 Non-radiation risk factors for thyroid cancer in the US Radiologic Technologists Study. *Am J Epidemiol* **171**:242–252.
6. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M 2008 Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* **371**:569–578.
7. Han JM, Kim TY, Jeon MJ, Yim JH, Kim WG, Song DE, Hong SJ, Bae SJ, Kim HK, Shin MH, Shong YK, Kim WB 2013 Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. *Eur J Endocrinol* **168**:879–886.
8. Harari A, Endo B, Nishimoto S, Ituarte PH, Yeh MW 2012 Risk of advanced papillary thyroid cancer in obese patients. *Arch Surg* **147**:805–811.
9. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. *Am J Med* **97**:418–428.
10. Mazzaferri EL, Kloos RT 2001 Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. *J Clin Endocrinol Metab* **86**:1447–1463.
11. Schlumberger MJ 1999 Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. *J Endocrinol Invest* **22**:3–7.
12. Smith RA, Cokkinides V, Brawley OW 2009 Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. *CA Cancer J Clin* **59**:27–41.
13. Schousboe JT, Kerlikowske K, Loh A, Cummings SR 2011 Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. *Ann Intern Med* **155**:10–20.
14. Shrime MG, Goldstein DP, Seaberg RM, Sawka AM, Rotstein L, Freeman JL, Gullane PJ 2007 Cost-effective management of low-risk papillary thyroid carcinoma. *Arch Otolaryngol Head Neck Surg* **133**:1245–1253.
15. Singer S, Lincke T, Gamper E, Bhaskaran K, Schreiber S, Hinz A, Schulte T 2012 Quality of life in patients with thyroid cancer compared with the general population. *Thyroid* **22**:117–124.
16. Simeone JF, Daniels GH, Hall DA, McCarthy K, Kopans DB, Butch RJ, Mueller PR, Stark DD, Ferrucci JT Jr, Wang CA 1987 Sonography in the follow-up of 100 patients with thyroid carcinoma. *AJR Am J Roentgenol* **148**:45–49.
17. Koike E, Noguchi S, Yamashita H, Murakami T, Ohshima A, Kawamoto H 2001 Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. *Arch Surg* **136**:334–337.
18. Katz JF, Kane RA, Reyes J, Clarke MP, Hill TC 1984 Thyroid nodules: sonographic-pathologic correlation. *Radiology* **151**:741–745.
19. American Joint Committee on Cancer. Cancer staging manual. Available at: www.cancerstaging.org/products/ajccguide.pdf (accessed January 2013).
20. National Heart, Lung, and Blood Institute. Definition of obesity. Available at: <http://www.nhlbi.nih.gov/health/health-topics/topics/obe/diagnosis.html> (accessed January 2013).
21. Pappa T, Alevizaki M 2014 Obesity and thyroid cancer: a clinical update. *Thyroid* **24**:190–199.
22. TreeAge Pro 2012 TreeAge Software, Inc., Williamstown, MA.
23. Pal T, Vogl FD, Chappuis PO, Tsang R, Brierley J, Renard H, Sanders K, Kantemiroff T, Bagha S, Goldgar DE, Narod SA, Foulkes WD 2001 Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. *J Clin Endocrinol Metab* **86**:5307–5312.
24. Hemminki K, Eng C, Chen B 2005 Familial risks for nonmedullary thyroid cancer. *J Clin Endocrinol Metab* **90**:5747–5753.
25. Xu L, Li G, Wei Q, El-Naggar AK, Sturgis EM 2012 Family history of cancer and risk of sporadic differentiated thyroid carcinoma. *Cancer* **118**:1228–1235.
26. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr 1995 Thyroid

- cancer after exposure to external radiation: a pooled analysis of seven studies. *Radiat Res* **141**:259–277.
27. Kim KW, Park YJ, Kim EH, Park SY, Park do J, Ahn SH, Jang HC, Cho BY 2011 Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis. *Head Neck* **33**:691–695.
28. Consorti F, Loponte M, Milazzo F, Potasso L, Antonaci A 2010 Risk of malignancy from thyroid nodular disease as an element of clinical management of patients with Hashimoto's thyroiditis. *Eur Surg Res* **45**:333–337.
29. Haymart MR, Repplinger DJ, Levenson GE, Elson DF, Sippel RS, Jaume JC, Chen H 2008 Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. *J Clin Endocrinol Metab* **93**:809–814.
30. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA 2006 Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. *J Clin Endocrinol Metab* **91**:4295–4301.
31. Kraimps JL, Bouin-Pineau MH, Amati P, Mothes D, Bonneau D, Marechaud R, Barbier J 1997 Familial papillary carcinoma of the thyroid. *Surgery* **121**:715–718.
32. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE 2002 Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab* **87**:489–499.
33. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC 2000 The Colorado thyroid disease prevalence study. *Arch Intern Med* **160**:526–534.
34. Mazzaferri EL 1993 Management of a solitary thyroid nodule. *N Engl J Med* **328**:553–559.
35. Mandel SJ 2004 A 64-year-old woman with a thyroid nodule. *JAMA* **292**:2632–2642.
36. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK, Frable WJ 2008 Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. *Diagn Cytopathol* **36**:425–437.
37. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* **19**:1167–1214.
38. Zanolco K, Pitelka-Zengou L, Dalal S, Elaraj D, Nayar R, Sturgeon C 2013 Routine on-site evaluation of specimen adequacy during initial ultrasound-guided fine needle aspiration of thyroid nodules: a cost-effectiveness analysis. *Ann Surg Oncol* **20**:2462–2467.
39. Durante C, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, Costante G, Meringolo D, Bruno R, Trulli F, Massa M, Maniglia A, D'Apollo R, Giacomelli L, Ronga G, Filetti S 2013 Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. *J Clin Endocrinol Metab* **98**:636–642.
40. American Cancer Society 2013 Thyroid Cancer Survival. Available at: <http://www.cancer.org/cancer/thyroidcancer/detailedguide/thyroid-cancer-survival-rates> (accessed January 2013).
41. Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ 2011 Use of radioactive iodine for thyroid cancer. *JAMA* **306**:721–728.
42. Clark OH, Duh Q-Y, Kebebew E. 2005 Textbook of Endocrine Surgery. Second edition. Elsevier Saunders, Philadelphia, PA.
43. Columbia University Department of Surgery. Staging and prognosis of thyroid cancer, adapted from the American Cancer Society. Available at: <http://columbiathyroidcenter.org/staging.html> (accessed January 2013).
44. American Cancer Society. Thyroid cancer survival by type and stage. Available at: www.cancer.org/cancer/thyroidcancer/detailedguide/thyroid-cancer-survival-rates (accessed January 2013).
45. Medicare. Medicare Clinical Laboratory Fee Schedule. Available at: www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html (accessed January 2013).
46. Zanolco K, Angelos P, Sturgeon C 2006 Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. *Surgery* **140**:874–881; discussion 881–872.
47. Quinn DI BV, Moyneur E. Direct medical costs associated with sorafenib and sunitinib treatment in patients with renal cell carcinoma using US medical claims data. Available at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=64&abstractID=20459 (accessed January 2013).
48. Zanolco K, Heller M, Elaraj D, Sturgeon C 2013 Cost effectiveness of intraoperative pathology examination during diagnostic hemithyroidectomy for unilateral follicular thyroid neoplasms. *J Am Coll Surg* **217**:702–710.
49. Centers for Medicare and Medicaid Services. Physician fee schedule search. Available at: www.cms.gov/apps/physician-fee-schedule/ (accessed January 2013).
50. Khalid AN, Hollenbeak CS, Quraishi SA, Fan CY, Stack BC Jr 2006 The cost-effectiveness of iodine 131 scintigraphy, ultrasonography, and fine-needle aspiration biopsy in the initial diagnosis of solitary thyroid nodules. *Arch Otolaryngol Head Neck Surg* **132**:244–250.
51. Cheung K, Roman SA, Wang TS, Walker HD, Sosa JA 2008 Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. *J Clin Endocrinol Metab* **93**:2173–2180.
52. Yip L, Farris C, Kabaker AS, Hodak SP, Nikiforova MN, McCoy KL, Stang MT, Smith KJ, Nikiforov YE, Carty SE 2012 Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. *J Clin Endocrinol Metab* **97**:1905–1912.
53. Papini E, Guglielmi R, Bianchini A, Crescenzi A, Tacogna S, Nardi F, Panunzi C, Rinaldi R, Toscano V, Pacella CM 2002 Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. *J Clin Endocrinol Metab* **87**:1941–1946.
54. Jeannon JP, Orabi AA, Bruch GA, Abdalsalam HA, Simo R 2009 Diagnosis of recurrent laryngeal nerve palsy after thyroidectomy: a systematic review. *Int J Clin Pract* **63**:624–629.
55. Duh Q-Y 2012 Thyroid cancer operations for obese patients: the bad news and the good news. *Arch Surg* **147**:811–812.
56. Jo VY, Stelow EB, Dustin SM, Hanley KZ 2010 Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology. *Am J Clin Pathol* **134**:450–456.
57. Ross DS 2002 Nonpalpable thyroid nodules—managing an epidemic. *J Clin Endocrinol Metab* **87**:1938–1940.

58. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW 2007 Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. *Cancer* **110**:1451–1456.
59. Centers for Medicare and Medicaid Services. MEDPAR inpatient hospital national data for fiscal year 2010—short stay inpatient diagnosis related groups. Available at www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareFeeforSvcPartsAB/MEDPAR.html (accessed January 2013).

Address correspondence to:
Avital Harari, MD
Assistant Professor of Surgery
Department of Surgery
University of California, Los Angeles
10833 LeConte Ave, Suite 72-215CHS
Los Angeles, CA 90095

E-mail: AHarari@mednet.ucla.edu